You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,328,094

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,328,094

Title:	Compound from the avermectin family for treating and/or preventing folliculitis
Abstract:	A compound from the avermectin family is described for use in treating and/or preventing folliculitis caused by anti-cancer agents and more particularly by agents for targeted therapy.
Inventor(s):	Kerob; Delphine (La Defense, FR), Gerber; Peter Arne (Dusseldorf, DE)
Assignee:	GALDERMA SA (Cham, CH)
Application Number:	15/550,643
Patent Claims:	1. A method of treating folliculitis caused by an anti-cancer agent, the method comprising administering an effective amount of a compound of the avermectin family to an individual subject in need thereof, wherein the folliculitis exhibits proliferation of Staphylococcus aureus. 2. The method as claimed in claim 1, wherein the anti-cancer agent is a chemotherapy agent or a targeted-therapy agent. 3. The method as claimed in claim 2, wherein the targeted-therapy agent is selected from the group consisting of agents which have an anti-EGFR activity and MEK-inhibiting agents. 4. The method as claimed claim 1, wherein the compound of the avermectin family is selected from the group consisting of ivermectin, avermectin, abamectin, doramectin, eprinomectin, selamectin, aversectin B, AB or C, emamectin B1b or latidectin. 5. The method as claimed in claim 1, wherein the compound of the avermectin family is ivermectin. 6. The method as claimed in claim 3, wherein the therapeutic agent having an anti-EGFR activity is selected from the group consisting of cetuximab, gefitinib, erlotinib, panitumumab lapatinib, and mixtures thereof. 7. The method as claimed in claim 3, wherein the MEK-inhibiting targeted-therapy agent is selected from the group consisting of trametinib, selumetinib, binimetinib and cobimetinib. 8. The method as claimed in claim 1, wherein the compound is a pharmaceutical composition. 9. The method as claimed in claim 8, wherein the composition is in a form suitable for topical administration. 10. The method as claimed in claim 9, wherein the composition is in the form of an emulsion, cream, lotion, gel, solution or salve. 11. The method as claimed in claim 1, wherein the composition comprises from 0.001% to 10% by weight of the compound of the avermectin family, relative to the total weight of the composition. 12. The method as claimed in claim 1, wherein the composition comprises 1% by weight of the compound of the avermectin family in comparison with the total weight of the composition. 13. The method as claimed in claim 11, wherein the composition comprises from 0.001% to 8% by weight of compound of the avermectin family. 14. The method as claimed in claim 11, wherein the composition comprises from 0.001% to 5% by weight of compound of the avermectin family. 15. The method as claimed in claim 11, wherein the composition comprises from 0.1% to 3% by weight of compound of the avermectin family.

Details for Patent 10,328,094

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2035-02-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2035-02-12
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006	⤷ Try a Trial	2035-02-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.